News Features The Hope Dealers: How Clinicians and New Tech Could End Unnecessary PAD Amputations L.A. McKeown December 24, 2020
News Conference News EAS 2020 Lp(a) and LPA Genetic Risk Score Both Predict Incident ASCVD: UK Biobank Michael O'Riordan October 07, 2020
News Conference News ESC 2020 VOYAGER PAD: CAD Subanalysis Finds Fewer CV, Limb Events With Rivaroxaban L.A. McKeown September 03, 2020
News Daily News CV Prevention Meds Underused in Hispanic, Latinx PAD Patients L.A. McKeown August 12, 2020
News Daily News PAD Patients Undertreated With Statins Despite Elevated CV Risk L.A. McKeown July 13, 2020
News Daily News Inflammation Plays Into the ASCVD Risk Associated With Lp(a): ACCELERATE Michael O'Riordan July 08, 2020
News Conference News ACC 2020 New Questions About Triple Therapy After PAD Revascularization: VOYAGER PAD Substudy L.A. McKeown April 02, 2020
Presentation ACC 2020 VOYAGER PAD Efficacy and Safety of Rivaroxaban in Patients with Symptomatic PAD undergoing Revascularization with and without Clopidogrel Presenter: William Hiatt March 29, 2020
News Conference News ACC 2020 Diabetes May Boost Benefits of COMPASS Dual Antithrombotic Approach Todd Neale March 28, 2020
News Daily News COMPASS Antithrombotic Approach Works Well in Prior-PCI Patients Todd Neale March 27, 2020